In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …

During the current coronavirus disease 2019 (COVID-19) pandemic, a variety of mutations
have accumulated in the viral genome of severe acute respiratory syndrome coronavirus 2 …

Since the first cases of COVID-19 were documented in Wuhan, China in 2019, the world has
witnessed a devastating global pandemic, with more than 238 million cases, nearly 5 million …

We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …

Since the first reports of a novel severe acute respiratory syndrome (SARS)-like coronavirus
in December 2019 in Wuhan, China, there has been intense interest in understanding how …

Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) genome are expected to be either deleterious and swiftly purged or relatively …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …

Many SARS-CoV-2 variants with naturally acquired mutations have emerged. These
mutations can affect viral properties such as infectivity and immune resistance. Although the …